RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:391504

Transient neonatal myasthenia gravis

medium confidenceSubtype of disorder

Also known as: NMG · Neonatal myasthenia gravis · Transient neonatal acquired myasthenia · Transient neonatal autoimmune myasthenia gravis

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

229

60th percentile

Trials

0

Interventional, condition-specific

Researchers

853

Distinct authors in sample

Gene link

CHRNG

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

Transient myasthenia gravis (MG) is a rare form of MG occurring in neonates born to mothers who have the disorder or specific circulating autoantibodies.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

transient neonatal acquired myasthenia · transient neonatal autoimmune myasthenia gravis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Strong — CHRNG

  2. LiteraturePresent

    229 matched papers (70 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 224 for broader category myasthenia gravis

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (CHRNG).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

229

229 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

229 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

70 in the last 10 years · medium confidence · 60th percentile (publications denominator)

Phrase hits: 229 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

853

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Eymard B10 papers · 2023

    Service de Neurologie, Hôpital de la Salpêtrière, Paris.

    Papers in Europe PMC
  2. 02
    Bach JF8 papers · 1997
    Papers in Europe PMC
  3. 03
    Morel E8 papers · 1997

    INSERM U25-CNRS UA 122, Hôpital Necker, Paris, France.

    Papers in Europe PMC
  4. 04
    Vernet-der Garabedian B6 papers · 1997

    INSERM U25, Hôpital Necker, Paris, France.

    Papers in Europe PMC
  5. 05
    Vincent A5 papers · 2023

    Department of Clinical Neurology and Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK. angela.vincent@imm.ox.ac.uk

    Papers in Europe PMC
  6. 06
    Abramsky O4 papers · 1992
    Papers in Europe PMC
  7. 07
    Brenner T4 papers · 1992
    Papers in Europe PMC
  8. 08
    Lefvert AK4 papers · 1995
    Papers in Europe PMC
  9. 09
    Chen H3 papers · 2022

    The Center for Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY, 11030, USA.

    Papers in Europe PMC
  10. 10
    Evoli A3 papers · 2020

    Istituto di Neurologia, Policlinico A. Gemelli IRCSS, Università Cattolica del S. Cuore, Rome, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 224 trials are registered for myasthenia gravis, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

224 interventional trials matched myasthenia gravis, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: myasthenia gravis

224

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

General rare disease registries you may be eligible for

These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Transient neonatal myasthenia gravis" OR "Neonatal myasthenia gravis" OR "Transient neonatal acquired myasthenia" OR "Transient neonatal autoimmune myasthenia gravis"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Transient neonatal myasthenia gravis" OR "Neonatal myasthenia gravis" OR "Transient neonatal acquired myasthenia" OR "Transient neonatal autoimmune myasthenia gravis" OR "CHRNG"

Recall-expansion terms: CHRNG

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"myasthenia gravis"

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: NMG

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T15:08:17.807Z